Cellectis Refocuses on In Vivo Genome Editing and Discontinues Two Programs
The board of directors of the Parisian biotechnology company approved on September 11, 2026 a reorientation of its activities toward the development of genome editing treatments administered directly to patients.
This decision is accompanied by the discontinuation of two candidate products in cell therapy and an organizational adjustment.
HEAL-101 and HEAL-201, Two Programs in Severe Dyslipidemias
The transformation is based on two flagship candidate programs described as promising at the preclinical stage: HEAL-101, a base editing candidate product in vivo targeting the APOC3 gene in severe hypertriglyceridemia, and HEAL-201, an epigenetic editing candidate product in vivo targeting the PCSK9 gene in severe hypercholesterolemia.
For each of these two programs, the company plans to initiate a phase 1 study in China at the initiative of an investigator. It indicates aiming to communicate preliminary clinical data in the second half of 2027 for HEAL-101 and in the first half of 2028 for HEAL-201.
Cellectis highlights a platform covering nuclease editing, base editing, epigenetic editing and transcriptional regulation, presented as a set of competencies built over more than twenty-five years.
Discontinuation of Lasmé-cel and Éti-cel and Organizational Adjustment
The company is terminating the development of its candidate products in cell therapy lasmé-cel and éti-cel, while seeking strategic partnership opportunities for these two assets. It justifies this decision by the evolution of the clinical and commercial environment in B-ALL and NHL, marked by advances in first-line protocols and the rise of bispecific antibodies and in vivo CAR-T approaches.
Cellectis indicates that it is adjusting its organization and resources in order to concentrate its efforts on its in vivo genome editing programs and to support its existing cell therapy partnerships with AstraZeneca, Allogene, Servier and Iovance. These measures, presented as subject to consultation with employee representative bodies, aim to extend the company's cash runway until the second half of 2028.
In this context, the listing of ordinary shares on Euronext Growth will be temporarily suspended this Monday, September 14, 2026, from market opening at 9:00 a.m. (Paris time) until the opening of the Nasdaq Global Market at 3:30 p.m. (Paris time).
